Windtree Therapeutics Faces Nasdaq Delisting Amid Compliance Failures
Nasdaq has initiated delisting proceedings against Windtree Therapeutics (WINT) for failing to maintain a minimum bid price of $1 per share, as mandated by its Listing Rule 5550(a)(2). Trading will halt on August 21, 2025, though the company vows to continue meeting regulatory reporting requirements.
Windtree's shares have collapsed over 99% year-to-date, closing at $0.11 before the suspension. The biopharma firm follows Bitcoin miner Argo Blockchain, which faced similar Nasdaq delisting actions in July for sub-$1 trading.
Notably, Windtree gained attention for its cryptocurrency investments, though the article cuts off before detailing specific digital asset exposures. The delisting reflects broader market pressures on small-cap firms struggling with compliance thresholds.
